HE3235 news from FierceBiotech
NewsSPOTLIGHT: Hollis-Eden skyrockets on preclinical cancer data
At the 2007 ASCO Breast Cancer Symposium, Hollis-Eden reported impressive data for HE3235, a preclinical candidate for breast cancer. HE3235 significantly inhibited the incidence of new tumors and... Read more...
| Press ReleasesPRESS RELEASE: Hollis-Eden Pharmaceuticals Presents HE3235 Update at ASCO Breast Cancer Symposium Hollis-Eden Pharmaceuticals Presents HE3235 Update at ASCO Breast Cancer Symposium Preclinical Data Show Lasting Anti-Tumor Effect of Novel Drug Candidate SAN DIEGO -- Hollis-Eden Pharmaceuticals, Read more >> |
Get more HE3235 coverage at:
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets
